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Abstract
The inferior colliculus (IC) is a major center of integration in
the ascending as well as descending auditory pathways,
where both excitatory and inhibitory amino acid neurotrans-
mitters play a key role. When normal input to the auditory
system is decreased, the balance between excitation and
inhibition in the IC is disturbed. We examined global changes
in gene expression in the rat IC 3 and 21 days following
bilateral deafening, using Affymetrix GeneChip arrays and
focused our analysis on changes in expression of neuro-
transmission-related genes. Over 1400 probe sets in the
Affymetrix Rat Genome U34A Array were identified as genes
that were differentially expressed. These genes encoded
proteins previously reported to change as a consequence of
deafness, such as calbindin, as well as proteins not previously
reported to be modulated by deafness, such as clathrin. A
subset of 19 differentially expressed genes was further
examined using quantitative RT–PCR at 3, 21 and 90 days
following deafness. These included several GABA, gly-
cine, glutamate receptor and neuropeptide-related genes.
Expression of genes for GABA-A receptor subunits b2, b3,
and c2, plus ionotropic glutamate receptor subunits AMPA 2,
AMPA 3, and kainate 2, increased at all three times.
Expression of glycine receptor a1 initially declined and then
later increased, while a2 increased sharply at 21 days. Gly-
cine receptor a3 increased between 3 and 21 days, but
decreased at 90 days. Of the neuropeptide-related genes
tested with qRT–PCR, tyrosine hydroxylase decreased
approximately 50% at all times tested. Serotonin receptor 2C
increased at 3, 21, and 90 days. The 5B serotonin receptor
decreased at 3 and 21 days and returned to normal by
90 days. Of the genes tested with qRT–PCR, only glycine
receptor a2 and serotonin receptor 5B returned to normal
levels of expression at 90 days. Changes in GABA receptor
b3, GABA receptor c2, glutamate receptor 2/3, enkephalin,
and tyrosine hydroxylase were further confirmed using
immunocytochemistry.
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Plasticity in the mature mammalian central nervous system is
often induced by changes in neuronal activity. This response,
called ‘activity-dependent plasticity’, can involve changes in
amino acid neurotransmitters and receptors which, in turn,
can reshape neuronal responses and information processing.
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The auditory system provides an excellent model for
examining activity-dependent plasticity, because the level
of neuronal activity can be easily manipulated. Deafness (full
or partial) and noise over-stimulation have been shown to
lead to plastic changes in the mature central auditory
pathways (Syka 2002; Moller 2005). Changes that have
been reported following deafness include changes in the
tonotopic map (Robertson et al. 1989; Rajan et al. 1993), in
cell size (Sie and Rubel 1992; Dodson et al. 1994; Lustig
et al. 1994; Lesperance et al. 1995; Willott and Bross 1996;
Moore et al. 1997; Niparko and Finger 1997; Araki et al.
1998; Edmonds et al. 1999; Niparko 1999; Nishiyama et al.
2000), changes in synaptic contacts and synapse morphology
(Kazee et al. 1995; Huchton et al. 1997; Ryugo et al. 1997;
Niparko 1999; Russell and Moore 2002; Lee et al. 2003), in
neurotransmitters and receptors as well as their release,
uptake and binding (Caspary et al. 1995; Milbrandt et al.
2000; Potashner et al. 2000; Vale and Sanes 2002), in ion
channels (Storey et al. 2002; Mhatre et al. 2004), in
transcription factors (Illing et al. 1999; Illing and Michler
2001; von Hehn et al. 2004), in oxygen reactive species
(Ohlemiller and Dugan 1999; Ohlemiller et al. 1999; Shi
et al. 2002), and in stress response molecules (Myers et al.
1992; Billings et al. 1995; Verstreken et al. 1996; Oh et al.
2000; Van Campen et al. 2002; Wang et al. 2002; Yeom
et al. 2003). These changes can lead to problems such as
poor speech perception and tinnitus when there is partial or
incomplete deafness and can influence the efficacy of
cochlear prostheses following profound deafness.
An auditory brainstem region in which activity-dependent
plastic changes have been well characterized is the inferior
colliculus (IC), a major center of integration in the ascending
as well as descending auditory pathways. Following deaf-
ness, there is a marked change in the balance of excitation
and inhibition, resulting in changes in synaptic strength,
inhibitory strength and evoked responses (Bledsoe et al.
1995; Wang et al. 1996; Mossop et al. 2000; Vale and Sanes
2002) These are associated with changes in inhibitory and
excitatory amino acids and their receptors, particularly with
changes in the production (Raza et al. 1994; Milbrandt et al.
2000; Mossop et al. 2000) and release (Bledsoe et al. 1995;
Caspary et al. 1995) of GABA, as well as changes in GABA
receptors (Caspary et al. 1995; Milbrandt et al. 2000; Vale
and Sanes 2000).
Given the large and varied number of activity-dependent
changes reported in the auditory brainstem following deaf-
ness, changes in expression for a large number of genes
might be expected in the IC following deafness. Genes
associated with amino acid neurotransmission and its regu-
lation would be specific candidates for differential expres-
sion. Gene microarrays provide a method of screening
thousands of genes simultaneously. Such an analysis can test
multiple amino acid neurotransmission genes, identifying
new genes that show changes, while confirming those
already shown by other methods. By using this method, we
can also identify genes associated with other known
deafness-related changes, as well as identify changes in
expression of genes associated with novel processes.
We therefore used Affymetrix rat U34AGeneChip arrays to
examine changes in gene expression in the rat IC at two times
following bilateral deafening. As expected, many genes
encoding proteins involved in neurotransmission showed
changes in expression. We verified a subset of these genes
using quantitative RT–PCR (qRT–PCR) and immunocyto-
chemistry. We were also able to identify genes associated with
other known changes with deafness as well as genes that have
not previously been shown to be activity dependent.
Materials and methods
Experimental design
Rats were checked for normal hearing by auditory brainstem
response (ABR) prior to the study and were randomly assigned to
either a group that received bilateral deafening or to an untreated,
normal-hearing group. Treated rats and the age-matched controls
were processed for gene microarrays at 3 and 21 days following
deafness and for qRT–PCR and immunocytochemistry at 3, 21 and
90 days following deafening. These time points were chosen based
on previous studies showing either transient or permanent changes
in neurotransmitter and receptors at these times (Bledsoe et al.
1995; Sato et al. 2000). For gene microarray experiments, rats were
randomly divided into three groups containing 18 animals per
group: Group 1, normal hearing; group 2, bilaterally deafened by
cochlear ablation and assessed at 3 days following deafening; and
group 3, bilaterally deafened by cochlear ablation and assessed at
21 days following deafening. Each of these three groups was further
divided into six subgroups containing three animals each. Therefore,
six experimental replicates were performed per group, with the
pooled inferior colliculi from three animals comprising one
replicate. Thus, there were six biological replicates per experimental
group, three groups and 18 total chips assessed. For qRT–PCR one
of the six replicates from each group was randomly selected and run
in triplicate on three separate occasions for each gene product
examined (21 in all). For immunocytochemistry, 12 additional
animals were analyzed, four in the normal group, three in the 3-days
deafened group, two in the 21-days deafened group, and three in the
90-days deafened group.
Cochlear ablation
Male Sprague–Dawley rats obtained from Charles River Laborat-
ories (Wilmington, MA, USA), were maintained on a 12-h reversed
light–dark cycle and had free access to food and water. All studies
were approved by the University Committee on the Use and Care of
Animals. Rats weighing 185–275 g were deeply anesthetized with a
mixture of ketamine (75 mg/kg) and xylazine (8 mg/kg). ABR
thresholds were measured at frequencies of 2, 10 and 20 kHz from
0 to 100 dB before surgery to confirm that all animals had normal
hearing. Animals were bilaterally deafened by mechanical ablation
of the cochlea. Hearing thresholds were again determined on
anesthetized animals by ABR 3, 21 or 90 days following ablation,
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to assess the degree of hearing loss. Only animals that sustained a
threshold shift of 80 dB or greater were included in the study. This
criterion for deafness was to ensure a homogenous group of
deafened animals.
RNA isolation
Rats were anesthetized with a lethal dose (0.8–1 mL) of Fatal Plus
(Vortech Pharmaceuticals, Dearborn, MI, USA) and decapitated.
Brains were rapidly removed and the right and left IC dissected
away from the remaining midbrain with fine-tipped forceps and
placed in RNAlater (Ambion, Austin, TX, USA). Tissues were
homogenized in Trizol (Invitrogen, Carlsbad, CA, USA) for 10 s
with a Tissue-Tearor homogenizer (Biospec Products Inc.,
Bartlesville, OK, USA). RNA was isolated using a modification of
the standard Trizol protocol. Briefly, chloroform was added to the
homogenate, vortexed briefly, and centrifuged at 14 000 g. The
aqueous phase was transferred to a Phase Lock Gel (heavy) tube
(Eppendorf/Brinkmann, Westbury, NY, USA) and extracted with
acid phenol : chloroform (1 : 1). The aqueous phase was decanted
and RNA was precipitated with isopropanol. Contaminants were
removed with RNeasy mini-spin columns (Qiagen, Chatsworth, CA,
USA). RNAwas eluted in 100 lL of diethyl pyrocarbonate (DEPC)
treated water. RNA concentration was determined by UV spectro-
photometry. RNA quality was assessed on an RNA 6000 Nano
LabChip (Agilent, Palo Alto, CA, USA) using an Agilent 2100
Bioanalyzer, to assess the integrity of the 18S and 28S rRNA bands.
Hybridization of Affymetrix GeneChips
This study utilized high-density oligonucleotide microarrays (Gene-
Chips, Affymetrix, Santa Clara, CA, USA) that detect the expression
levels of 8799 known genes and expressed sequence tags (ESTs; Rat
Genome U34A Array). Preparation of cRNA, hybridization and
scanning of the arrays were performed according to manufacturer’s
protocols. Briefly, 5 lg of total RNA was used to generate double-
stranded cDNA by reverse transcription using a cDNA synthesis kit
(Superscript Choice System, Gibco-BRL, Rockville, MD, USA) that
employs an oligo(dT)24 primer containing a T7 RNA polymerase
promoter 5¢ to the poly(dT) (Genset, La Jolla, CA, USA), followed
by second-strand synthesis. Biotin-labeled cRNAwas prepared from
the double-stranded cDNA by in vitro transcription with T7 RNA
polymerase in the presence of biotin-11-CTP and biotin-16-UTP
(Enzo, Farmingdale, NY, USA), then purified over RNeasy columns
(Qiagen). Fifteen micrograms of cRNA was fragmented at 94C for
35 min in 40 mM Tris-acetate (pH 8.1), 100 mM potassium acetate,
and 30 mM magnesium acetate, then added to 300 lL of hybrid-
ization cocktail (100 mM MES, 1 M NaCl, 20 mM EDTA, 0.01%
Tween 20) containing 0.1 mg/mL herring sperm DNA (Promega,
Madison, WI, USA), and 500 lL/mL acetylated bovine serum
albumin (BSA; Gibco-BRL). Prior to hybridization, the cocktails
were heated to 94C for 5 min, equilibrated at 45C for 5 min, then
centrifuged (16 000 g) at room temperature (27C) for 5 min.
Aliquots of this hybridization cocktail containing 10 lg of frag-
mented cRNA were hybridized to HuGeneFL arrays at 45C for
16 h in a rotisserie oven at 60 r.p.m. The arrays were washed under
non-stringent conditions (6 · Saline Sodium Phosphate EDTA
(SSPE) at 25C), followed by a stringent wash [100 mM 2-(N-
morpholino) ethane sulphonic Acid, MES) (pH 6.7), 0.1 M NaCl,
0.01% Tween 20 at 50C], then stained with streptavidin-phyco-
erythrin (Molecular Probes, Eugene, OR, USA), washed with
6 · SSPE, incubated with biotinylated anti-streptavidin IgG, stained
again with streptavidin–phycoerythrin, and washed again with
6 · SSPE. Arrays were scanned with the GeneArray scanner
(Affymetrix) and image analysis was performed with GeneChip
software (Affymetrix).
Microarray data analysis
Affymetrix U34A GeneChips contain a set a set 16 pairs of short
(25-mer) oligonucleotide probes for each gene (a probe set). The
paired probes consist of a ‘perfect match’ (PM) probe that is
identical to a particular sequence of the gene and a ‘mismatch’
(MM) probe that has the central base switched with its complement.
PM probes are used to estimate transcript abundance, whereas MM
probes are intended to provide a measure of background binding for
each PM probe. Overall transcript abundance for each gene is
estimated by calculating a summary statistic for each probeset (an
‘expression value’). There are several methods for computing
expression values [MAS5, dChip, robust multiarray average (RMA),
etc.]; we chose to use an RMA as implemented in the ‘affy’ package
of Bioconductor (http://www.bioconductor.org). RMA performs
three operations: probe-specific background correction to compen-
sate for non-specific binding using PM distribution rather than PM-
MM value; probe-level multichip quantile normalization to unify
PM distributions across all chips; and robust probe-set summary of
the log-normalized probe-level data by median polishing. This
method is based on recent studies that used dilution and spike-in
experiments, adding known amount of specific transcripts to the
preparation, to evaluate different methods of calculating intensity
values and normalizing GeneChip data. RMA was directly com-
pared with other GeneChip analysis software such as dChip or
MAS5 (Irizarry et al. 2003a,b). These studies found that RMA gave
the most accurate representation of ‘known’ datasets.
Statistical analysis
Statistical Analysis of Microarrays (SAM; http://www-stat.stan-
ford.edu/tibs/SAM) was used to perform two-sample t-tests on the
log transformed (log base 2) intensity values obtained from 18
GeneChips (six biological replicates from each of three experimental
groups). By permuting the data to estimate the percentage of genes
identified at random, a user of SAM can calculate a false discovery
rate (FDR), the probability that the change in expression of a given
gene is erroneously called significant, and thereby assign statistical
significance to differences in intensity values across experimental
groups (Tusher et al. 2001). Genes with an FDR of 5% or less were
considered significant in the current study.
Quantitative RT–PCR
A subset of significantly expressed genes was selected for further
study, based on the importance of amino acid neurotransmitters and
neuropeptides in the ascending auditory pathways. Real-time PCR
was performed on a randomly selected pool of RNA (from pools
used in GeneChip experiments) 3 and 21 days following cochlear
ablation. The 90-day group consisted of three pools of mRNA, each
derived from three animals. cDNAwas generated from 1 lg of total
RNA using Superscript II (Invitrogen). The cDNA was diluted to
200 lL and 2.5 lL was used for each real-time PCR reaction. Real-
time PCR reactions were performed using Assays-by-Design
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TaqMan MGB assays (Applied Biosystems, Foster City, CA, USA),
which use 5¢ nuclease chemistry with two unlabeled PCR primers
(Table S1; 900 lM each) and an FAM dye-labeled TaqMan minor
groove binder (MGB) probe (250 lM), and TaqMan Universal PCR
Master Mix. Reactions were performed on an ABI Prism 7900, and
results were analyzed using ABI Prism 7900 Sequence Detection
System software (Applied Biosystems).
We tested 19 neurotransmission-related genes at the 3-, 21- and
90-day time points in triplicate. These genes were GABA-A
receptors b2, b3, c1, c2; glutamate decarboxylase 2; glycine a1, a2,
a3; glutamate receptors AMPA 2 (GluR 2), AMPA 3 (GluR 3);
glutamine synthetase 1 (glns); glutaminase (gls); glutamate receptor
kainate 2 (GluR K2); 5-hydroxytryptamine (serotonin) receptors
5B, 2C; pre-proenkephalin; pre-pronociceptin (neuropeptide noci-
ceptin); activity and neurotransmitter-induced early gene protein 4
(ania-4); and tyrosine hydroxylase (TH).
We used the 2–D1
D
2
Ct method to calculate the fold change in gene
expression (Livak and Schmittgen 2001). For each gene at each time
point, we determined the cycle threshold (Ct), the cycle number at
which PCR products are increasing exponentially. To normalize the
data, the threshold value for ribosomal subunit S16 was subtracted
from threshold values for each gene at each time point (D1). Then
the threshold value of the control group for each gene was
subtracted from the experimental threshold value (D2). The final




Ct)], we calculated the relative differences between experi-
mental and control groups as fold change. The average value of
triplicate PCR reactions was normalized to the average value for the
S16 ribosomal protein for each sample and then compared with the
expression value of the control group.
Immunocytochemistry
From the group of genes confirmed by qRT-PCR, we selected five
genes to determine the cellular localization and distribution of their
products in the IC, using immunocytochemistry. Two of these genes,
TH and pre-proenkephalin, showed decreases and three genes,
GluR 2/3, GABA-A receptor subunit b3 and subunit c2, increased
in expression. The distribution of labeled neurons and processes
were examined in a qualitative manner in sections from the
brachium to the mid rostro-caudal region of the IC. Normal animals
(n ¼ 4) were compared with eight deafened animals (three 3-day
deaf, two 21-day deaf, three 90-day deaf). Animals were anesthe-
tized with Fatal Plus (0.8–1 mL) and then received vascular
perfusion with phosphate buffer followed by a fixative containing
4% paraformaldehyde in phosphate buffer. Brains were removed
and post-fixed for 2 h in the same fixative. Brains were then rinsed
in phosphate-buffered saline (PBS) and placed in 10% sucrose in
PBS for 12–16 h at 4C. The auditory brainstem was then rapidly
frozen onto a cryostat chuck using OCT compound (Fisher
Scientific, Pitsburgh, PA, USA) and 12 lm frozen coronal sections
were cut through the IC. Sections were mounted on Fisher Plus
slides and antibodies were used to localize the protein products of
these five differentially expressed genes within the IC.
Cryostat sections were incubated with a primary antibody, TH
(Novus Biologicals, Littleton, CO, USA, 1 : 400), pre-proenkeph-
alin (PPENK; Fitzgerald Industries, Concord, MA, USA; 1 : 100),
GluR 2/3 (Chemicon, Temecula, CA, USA; 1 : 50), GABA b3
(Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1 : 50), or
GABA c2 (Alomone Laboratories, Jerusalem, Israel; 1 : 4000)
and normal serum from the species in which the secondary antibody
was raised (donkey or goat; 1 : 200; Jackson Laboratories Bar
Harbor, ME, USA) in PBS with 0.3% triton X-100 for 24 h at 4C in
a humid chamber. All subsequent incubations and rinses (three times
for 5 min in PBS) were carried out at room temperature. The sections
were then rinsed and incubated for 1 h with Alexa fluor 594 donkey
anti-goat (1 : 100) or Alexa fluor 568 goat anti-rabbit (1 : 100)
secondary antibody (Molecular Probes) in 0.3% triton X-100. After
rinsing, slides were coverslipped using gel/mount (Biomedia Corp.,
Foster City, CA, USA).
Histological analysis
Images of immunoreactive cells, fibers, and puncta in the IC were
obtained from sections using a Zeiss LSM confocal microscope.
The characteristics: somatic, dendritic, punctate, as well as the
amount and location of the immunoreactive label within the IC,
were noted for each experimental group, and a blind qualitative
assessment was made by two investigators. For each antibody, a
z-series was collected for each experimental group studied. The
z-series was then montaged and one maximum projection image
compiled.
Results
Identification of differentially expressed genes following
deafening
From the 8799 probe sets interrogated on the Affymetrix
GeneChips, we found over 1400 probe sets that showed
differential expression at either 3 or 21 days following
deafness, with a false discovery rate (FDR) of 5% or less. Of
these, 411 showed increased expression after 3 days of
deafness, and 38 had decreased expression (Table S2). By
21 days following deafness, 700 probe sets had increased
expression and 331 decreased (Table S3). With the additional
restriction of a twofold or greater increase in expression, 38
probe sets met this criterion at 3 days (Table 1) and 57 probe
sets at 21 days (Table 2). With the additional restriction of a
decrease of approximately 20% or more, 34 probe sets
showed decreased expression 3 days following deafness
(Table 3) and 104 decreased at 21 days following deafness
(Table 4).
Genes showing the largest increase in expression included
several that encode proteins involved in neurotransmission,
such as synaptosomal-associated protein (SNAP 25),
GABA-A receptor epsilon, and microtubule-associated pro-
tein 2 (MAP2; Tables 1 and 2). Genes with the greatest
decrease in expression included pre-proenkephlin (PENK),
early growth response 1 (ERG1), and activity-regulated
cytoskeletal-associated protein (ARC; Tables 3 and 4).
Among those probe sets showing large increases or decreases
in expression, several were ‘unknowns’, or genes that have
not yet been identified. Of the 1480 genes showing
significant differential expression, 83 were classified as
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unknown, 191 were expressed sequence tags (ESTs) and 119
were transcripts that represent a different region of one of the
known genes. This left 1087 known genes (Tables S2 and S3).
As a first step in understanding functions of differen-
tially expressed genes, we used the gene ontology (GO)
classification of genes (http://www.godatabase.org/cgi-bin/
Table 1 Genes with greater than 2 fold increase in expression 3 days following deafness
Gene Title UniGene ID Fold Change q-value (%) Probe Set ID
Unknown Unknown 3.97 0.40 M13101cds_f_at
aquaporin 4 Rn.90091 3.97 0.40 U14007_at
Unknown Unknown 3.77 0.40 U83119_f_at
LINE retrotransposable element 3 Unknown 3.75 0.40 M13100cds#6_f_at
Unknown Unknown 3.68 0.40 X53581cds#5_f_at
Unknown Unknown 3.65 0.40 X05472cds#1_s_at
Unknown Unknown 3.36 0.40 X61295cds_s_at
LINE retrotransposable element 3 Unknown 3.35 0.40 M13100cds#2_s_at
visinin-like 1 Rn.105934 3.22 0.40 D10666_at
Unknown Unknown 3.17 0.40 X07686cds_s_at
synaptosomal-associated protein Rn.107689 3.09 0.40 AB003991_g_at
LINE retrotransposable element 3 Unknown 2.92 0.40 M13100cds#4_f_at
synaptosomal-associated protein Rn.107689 2.84 0.40 AB003992_s_at
synaptosomal-associated protein Rn.107689 2.59 0.40 AB003991_at
Similar to pinin; DNA segment, Chr 12,
ERATO Doi 512, expressed
(LOC368070), mRNA
Rn.38987 2.59 0.40 rc_AI639151_at
LINE retrotransposable element 3 Unknown 2.54 0.40 M13100cds#3_f_at
LINE retrotransposable element 3 Unknown 2.53 0.40 M13100cds#5_s_at
Transcribed seq. with moderate similarity to
protein pdb:1LBG (E. coli) B Chain B,
Lactose Operon Repressor Bound To 21-Base
Pair Symmetric Operator Dna,
Alpha Carbons Only
Rn.24387 2.36 0.40 rc_AA891476_at
cadherin 22 Rn.108785 2.35 0.40 D83349_at
Similar to RNA-binding region (RNP1, RRM)
containing 2; splicing factor (CC1.3); coactivator of
activating protein-1 and estrogen
receptors (LOC362251), mRNA
Rn.8555 2.33 0.40 rc_AA800126_at
Unknown Unknown 2.31 0.40 X53581cds#3_f_at
Similar to heterogeneous nuclear
ribonucleoprotein A2/B1 (LOC362361), mRNA
Rn.4057 2.25 0.40 rc_AA799511_g_at
Ac1054 mRNA, complete cds Rn.3412 2.25 0.40 rc_AA893212_at
gamma-aminobutyric acid A receptor, alpha 1 Unknown 2.18 0.40 L08490cds_at
Transcribed sequences Rn.25117 2.18 0.40 rc_AA799804_at
microtubule-associated protein 2 Rn.10484 2.17 0.40 X17682_s_at
Transcribed sequences Rn.98479 2.15 0.40 rc_AA874873_at
Similar to N-terminal aceyltransferase 1 (LOC310399), mRNA Rn.12587 2.14 2.89 rc_AI177404_at
microtubule-associated protein 2 Rn.10484 2.13 0.40 X53455cds_s_at
catalase Rn.3001 2.07 0.40 rc_AA926149_g_at
Similar to heterogeneous nuclear
ribonucleoprotein A2/B1 (LOC362361), mRNA
Rn.4057 2.06 0.40 rc_AA799511_at
ectonucleotide pyrophosphatase/phosphodiesterase 2 Rn.20403 2.06 0.40 D28560_at
Nclone10 mRNA Rn.32307 2.05 0.40 rc_AI071866_s_at
diacylglycerol kinase, beta Rn.11413 2.04 0.71 rc_AA818983_at
LINE retrotransposable element 3 Unknown 2.04 0.40 M13100cds#1_g_at
chimerin (chimaerin) 1 Rn.11166 2.01 1.39 X67250_at
solute carrier family 3, member 1 Rn.11196 2.01 0.40 M80804_s_at
Transcribed sequences Rn.22663 2.00 0.40 rc_H31859_at
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Table 2 Genes with greater than 2 fold increase in expression 21 days following deafness
Gene Title UniGene ID Fold Change q-value (%) Probe Set ID
aquaporin 4 Rn.90091 4.32 0.31 U14007_at
Unknown Unknown 4.26 0.54 M13101cds_f_at
LINE retrotransposable element 3 Unknown 4.01 0.54 M13100cds#6_f_at
Unknown Unknown 4.00 0.54 U83119_f_at
Unknown Unknown 3.99 0.63 X05472cds#1_s_at
Unknown Unknown 3.91 0.31 X53581cds#5_f_at
Unknown Unknown 3.85 0.63 X61295cds_s_at
LINE retrotransposable element 3 Unknown 3.61 0.63 M13100cds#2_s_at
LINE retrotransposable element 3 Unknown 3.54 1.17 M13100cds#4_f_at
Unknown Unknown 3.51 0.63 X07686cds_s_at
Similar to pinin; DNA segment, Chr 12,
ERATO Doi 512, expressed (LOC368070), mRNA
Rn.38987 3.20 0.31 rc_AI639151_at
visinin-like 1 Rn.105934 3.03 0.31 D10666_at
synaptosomal-associated protein Rn.107689 2.94 0.31 AB003991_g_at
LINE retrotransposable element 3 Unknown 2.92 0.31 M13100cds#3_f_at
synaptosomal-associated protein Rn.107689 2.86 0.31 AB003992_s_at
LINE retrotransposable element 3 Unknown 2.82 1.38 M13100cds#5_s_at
Nclone10 mRNA Rn.32307 2.75 0.31 rc_AI071866_s_at
Unknown Unknown 2.71 0.54 X53581cds#3_f_at
Similar to trinucleotide repeat containing 6; EDIE;
GW182 autoantigen (LOC308971), mRNA
Rn.6839 2.67 0.31 rc_AA875500_at
Similar to N-terminal aceyltransferase 1 (LOC310399), mRNA Rn.12587 2.58 0.31 rc_AI177404_at
synaptosomal-associated protein Rn.107689 2.52 0.31 AB003991_at
Transcribed seq. with moderate similarity to protein
pdb:1LBG (E. coli) B Chain B, Lactose Operon Repressor
Bound To 21-Base Pair Symmetric Operator Dna,
Alpha Carbons Only
Rn.24387 2.49 0.31 rc_AA891476_at
microtubule-associated protein 2 Rn.10484 2.37 1.38 X17682_s_at
LINE retrotransposable element 3 Unknown 2.32 0.63 M13100cds#1_g_at
catalase Rn.3001 2.27 0.31 rc_AA926149_g_at
myristoylated alanine rich protein kinase C substrate Rn.9560 2.24 0.31 rc_AA955167_s_at
Unknown Unknown 2.24 2.10 X05472cds#3_f_at
Transcribed sequences Rn.98479 2.22 0.31 rc_AA874873_at
Rattus norvegicus focal adhesion kinase
(FAK) mRNA, alternative 5’UTR
Rn.806 2.22 0.31 rc_AA874926_at
Similar to heterogeneous nuclear ribonucleoprotein
A2/B1 (LOC362361), mRNA
Rn.4057 2.20 0.31 rc_AA799511_g_at
microtubule-associated protein 2 Rn.10484 2.20 2.08 rc_AI228850_s_at
Transcribed sequences Rn.15385 2.19 0.31 rc_AI639410_s_at
microtubule-associated protein 2 Rn.10484 2.19 1.64 X53455cds_s_at
gamma-aminobutyric acid A receptor, alpha 1 Unknown 2.18 0.54 L08490cds_at
Transcribed sequences Rn.16596 2.17 0.31 rc_AI638960_g_at
Similar to RNA helicase A (LOC304859), mRNA Rn.107359 2.17 0.31 rc_AI639188_at
dynamin 1-like Rn.10830 2.12 0.31 AF020212_s_at
LIC-2 dynein light intermediate chain 53/55 Rn.31981 2.11 0.31 rc_AA891132_s_at
chimerin (chimaerin) 1 Rn.11166 2.11 0.31 X67250_at
Ac1054 mRNA, complete cds Rn.3412 2.11 2.08 rc_AA893212_at
solute carrier family 24 (sodium/potassium/calcium exchanger),
member 2
Rn.74242 2.11 0.31 AF021923_at
sodium channel, voltage-gated, type 2, alpha 1 polypeptide Rn.89192 2.11 0.31 M22254_at
Similar to cAMP-dependent protein kinase, beta-2-catalytic
subunit (PKA C-beta-2) (LOC310986), mRNA
Rn.3502 2.10 5.03 D10770_s_at
casein kinase II beta subunit Rn.11095 2.09 0.31 L15619_at
phospholipase C, beta 1 Rn.45523 2.09 0.31 L14323_at
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amigo/go.cgi), which assigns differentially expressed genes
to groups based on molecular function and biological
processes (Tables S2 and S3). Of these genes, over 300 in
the 3-day deaf group and over 600 in the 21-day deaf
group could not be classified, either because they were
unknown genes or because they have not been formally
assigned a molecular function or biological process
based on GO terminology. Nonetheless, we were able to
identify many neurotransmitter-related genes (Table 5 and
Tables S2 and S3) that showed changes in expression
and may contribute to auditory plasticity following
deafening.
Glutamate-related changes in expression
GeneChip analysis identified many glutamate-related genes
with significant and sustained increases in expression
following deafening (Table 5). Of these excitatory neuro-
transmission related genes, five were further assessed with
qRT-PCR and showed comparable changes (Fig. 1a). GluR 2
showed significant increases of 2.7-fold at 3 days, 2.9-fold at
21 days and 1.7-fold at 90 days. GluR 3 expression
increased 3.3-fold and 3.0-fold at 3 and 21 days, respect-
ively, and was still 2.7-fold higher than the control at
90 days. The expression of GluR K2 increased 2.5-fold at
3 days, 2.6-fold at 21 days, and was still 1.7-fold higher at
90 days. Similarly, glutaminase expression increased more
than a 3-fold at both 3 and 21 days, and was still 2.6-fold
higher at 90 days. Glutamine synthetase (glns) expression
did not increase following deafening, with no significant
change in glns expression at 3 days, and a modest decrease at
21 days. Similarly, qRT-PCR detected no change in expres-
sion (< 15%) at 3 and 21 days, with a somewhat greater
(24%) decrease at 90 days. None of the glutamate-related
transcripts returned to normal levels of expression by
90 days (Table 5).
GABA-A receptor subunits
Increased gene expression was seen in the three major types
(a, b and c) of GABA-A receptor subunits using GeneChip
analysis (Table 5). The b2, b3, c1 and c2 subunits of this
inhibitory receptor were further investigated with qRT–PCR
(Fig. 1b). GABA-A receptor b2 expression increased more
than 4-fold at 3 and 21 days, and was still 3-fold higher at
90 days following deafening. GABA-A b3 and c2 mNRA
levels were > 2-fold higher at 3 and 21 days, with a return
towards normal levels at 90 days. GABA-A receptor c1
subunit mRNA levels increased in the 3-day deaf group by
GeneChip analysis, while the qRT-PCR data did not show
an increase until 21 days and showed a return to near
normal levels at 90 days. For GAD 65 there were small
increases of 1.28-, 1.51- and 1.33-fold at 3, 21 and 90 days,
respectively.
Glycine receptor subunits
GeneChip results for the a2 subunit of the glycine receptor
showed a 1.6-fold increase in expression at 3 and 21 days
(Table 5), while qRT–PCR detected little change (below
15%) at 3 days, a 2.9-fold increase at 21 days, and a return to
normal levels of expression by 90 days following deafening
(Fig. 1c). GeneChip analysis detected no significant change
in the expression of glycine receptors a1 or a3 (Table 5), and
qRT–PCR detected little change (below 15%) in glycine
receptor subunit a1 at 3 days. By qRT–PCR, there was a
slight increase of 30% in glycine a1 at 21 days and an almost
1.5-fold increase by 90 days (Fig. 1c and Table 5). Glycine
receptor a3 had increased levels of expression (2.4-, 3.5- and
2.0-fold, respectively) at each of these three time points.
Other genes assessed by qRT–PCR
While GeneChip analysis did not detect a decrease in TH
until 21 days (Table 5), qRT–PCR showed an approxi-
Table 2 Continued
Gene Title UniGene ID Fold Change q-value (%) Probe Set ID
gap junction membrane channel protein alpha 1 Rn.10346 2.08 3.49 rc_AI029183_s_at
glutamate receptor, ionotropic, 2 Rn.91361 2.07 1.13 M38061_at
discs, large homolog 1 (Drosophila) Rn.89331 2.07 0.31 U14950_at
matrin 3 Rn.29774 2.06 0.31 M63485_at
Similar to RNA-binding region (RNP1, RRM) containing 2;
splicing factor (CC1.3); coactivator of activating protein-1
and estrogen receptors (LOC362251), mRNA
Rn.8555 2.06 0.31 rc_AA800126_at
Transcribed sequences Rn.25117 2.06 0.31 rc_AA799804_at
Transcribed sequences Rn.22663 2.05 0.63 rc_H31859_at
gamma-aminobutyric acid A receptor, gamma 2 Unknown 2.05 0.31 L08497cds_at
chimerin (chimaerin) 1 Rn.11166 2.04 0.31 rc_AA894317_s_at
dynamin 1-like Rn.10830 2.04 0.31 AF019043_at
solute carrier family 3, member 1 Rn.11196 2.02 3.49 M80804_s_at
Transcribed sequences Rn.15956 2.00 0.31 rc_AI639088_s_at
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mately 50% decrease in TH expression at 3, 21 and
90 days following deafness (Fig. 1d). Prepronociceptin
(PNOC) and pre-proenkephalin (PENK) expression levels
also decreased at these three times. Serotonin receptor 5B
(5-HT 5B) decreased approximately 20% at 3 and 21 days
following deafness, but returned to normal by 90 days.
The activity- and neurotransmitter-induced gene, ANIA4,
had comparable slight increases in expression at 3 days
with both GeneChip analysis and qRT–PCR. There was,
however, a difference at 21 days, where an increase was
seen in the GeneChip analysis, while there was a large
decrease in expression (80–90%) at 21 and 90 days
detected by qRT–PCR.
Immunocytochemical distribution of differentially
expressed genes in the IC
Immunocytochemistry was used to examine the distribution
of five proteins in the IC; GABA b3, GABA c2, glutamate
receptor 2/3 (Fig. 2), TH, and PPENK (Fig. 3). These
immunolabeling studies identified the neurons and cellular
elements containing products ultimately produced by the
gene. We also examined whether changes in expression
following deafness could be translated into changes in
production and/or localization and whether the changes were
sufficient to be appreciated in a qualitative appraisal.
Comparing the 3- and 21-day deafened group with the
normal group, there were not sufficient differences in the
Table 3 Genes with greater than 1.25 fold (25%) decrease in expression 3 days following deafness
Gene Title UniGene ID Fold Change Deaf / Normal q-value (%) Probe Set ID
early growth response 1 Rn.9096 -3.91 0.26 0.40 AF023087_s_at
Unknown Unknown -3.30 0.30 0.40 U75397UTR#1_s_at
early growth response 1 Rn.9096 -3.23 0.31 0.40 M18416_at
VGF nerve growth factor inducible Rn.9704 -2.83 0.35 0.40 M74223_at
galectin-related inter-fiber protein Rn.26894 -2.22 0.45 0.40 AF082160_at
Similar to testican-2 protein (LOC361840), mRNA Rn.66831 -2.08 0.48 4.02 rc_AI639294_at
activity regulated cytoskeletal-associated protein Rn.10086 -1.82 0.55 0.40 U19866_at
preproenkephalin, related sequence Rn.10015 -1.80 0.55 0.40 S49491_s_at
Unknown Unknown -1.72 0.58 1.98 rc_AI014135_g_at
hydroxysteroid 11-beta dehydrogenase 1 Rn.888 -1.61 0.62 0.40 rc_AI105448_at
Similar to Leucine-rich repeat-containing 8
(LOC311846), mRNA
Rn.33512 -1.56 0.64 2.89 rc_AA875002_at
Similar to carboxylesterase (LOC291863), mRNA Rn.108790 -1.51 0.66 5.46 rc_AA800851_s_at
Transcribed sequences Rn.3130 -1.48 0.68 1.98 rc_AA874803_g_at
Rgc32 protein Rn.3504 -1.46 0.68 0.93 AF036548_g_at
Rat mRNA for beta-tubulin T beta15 Rn.37849 -1.42 0.70 0.40 X03369_s_at
Unknown Unknown -1.41 0.71 1.98 X03347cds_g_at
protein tyrosine phosphatase, receptor type, N Rn.11097 -1.41 0.71 4.02 D38222_s_at
Max Rn.4210 -1.40 0.71 2.89 D14448_s_at
calcium/calmodulin-dependent protein kinase II alpha subunit Rn.107499 -1.40 0.71 4.02 J02942_at
phosphoglycerate mutase 1 Rn.123549 -1.40 0.72 5.46 rc_AI169417_s_at
chemokine (C-X3-C motif) ligand 1 Rn.107266 -1.38 0.73 0.40 AF030358_g_at
synaptic vesicle glycoprotein 2 a Rn.11264 -1.37 0.73 5.46 L05435_at
Unknown Unknown -1.37 0.73 1.39 U17837UTR#1_at
protein kinase, cAMP-dependent, catalytic, alpha Rn.103828 -1.37 0.73 1.98 X57986mRNA_s_at
farensyl diphosphate synthase Rn.2848 -1.36 0.73 2.89 rc_AI180442_at
phosphodiesterase 4A Rn.91357 -1.36 0.74 2.89 M25348_s_at
ATP synthase, H+ transporting, mitochondrial F1 complex,
epsilon subunit
Rn.3454 -1.36 0.74 2.89 rc_AI171844_g_at
Similar to 2700038E08Rik protein (LOC293725), mRNA Rn.43300 -1.36 0.74 4.02 rc_AA860024_at
pleckstrin homology, Sec7 and coiled/coil domains 3 Rn.10673 -1.33 0.75 2.89 U83897_at
Similar to mitochondrial ribosomal protein S6
(LOC288253), mRNA
Rn.41455 -1.33 0.75 5.46 rc_AI639387_at
laminin receptor 1 (67kD, ribosomal protein SA) Rn.999 -1.29 0.77 5.46 D25224_at
proteasome (prosome, macropain) subunit, beta type 4 Rn.6169 -1.28 0.78 4.02 L17127_g_at
Unknown Unknown -1.28 0.78 4.02 D13623_g_at
Transcribed sequences Rn.6620 -1.27 0.79 1.98 rc_AA800693_g_at
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Table 4 Genes with greater than 1.25 fold (25%) decrease in expression 21 days following deafness
Gene Title UniGene ID Fold Change Deaf / Normal q-value (%) Probe Set ID
VGF nerve growth factor inducible Rn.9704 -2.72 0.37 0.31 M74223_at
early growth response 1 Rn.9096 -2.18 0.46 3.49 AF023087_s_at
Unknown Unknown -2.02 0.49 5.03 U75397UTR#1_s_at
serum/glucocorticoid regulated kinase Rn.4636 -1.98 0.51 5.03 L01624_at
protein tyrosine phosphatase, non-receptor type 16 Rn.98260 -1.83 0.55 2.08 S74351_s_at
protein tyrosine phosphatase, non-receptor type 16 Rn.98260 -1.82 0.55 3.49 S81478_s_at
preproenkephalin, related sequence Rn.10015 -1.82 0.55 0.31 S49491_s_at
activity regulated cytoskeletal-associated protein Rn.10086 -1.79 0.56 0.31 U19866_at
Similar to carboxylesterase (LOC291863), mRNA Rn.108790 -1.77 0.56 0.54 rc_AA800851_s_at
ATP-binding cassette, subfamily C (CFTR/MRP), member 8 Rn.11187 -1.74 0.58 3.49 rc_AA799786_s_at
nuclear factor of kappa light chain gene
enhancer in B-cells inhibitor, alpha
Rn.12550 -1.65 0.61 1.64 X63594cds_g_at
neuronal d4 domain family member Rn.42906 -1.61 0.62 4.54 X66022mRNA#1_s_at
immediate early gene transcription factor NGFI-B Rn.10000 -1.61 0.62 3.49 U17254_g_at
synaptic vesicle glycoprotein 2 a Rn.11264 -1.60 0.63 2.10 L05435_at
Similar to talin (LOC313494), mRNA Rn.7715 -1.57 0.64 5.03 rc_AA800962_at
protein tyrosine phosphatase, non-receptor type 16 Rn.98260 -1.55 0.64 1.13 U02553cds_s_at
Similar to RIKEN cDNA 1110020C13 (LOC363004), mRNA Rn.2990 -1.53 0.65 3.49 rc_AA800199_at
Similar to transformation/transcription
domain-associated protein (LOC288471), mRNA
Rn.92036 -1.52 0.66 2.34 rc_AA800513_at
nuclear factor of kappa light chain gene
enhancer in B-cells inhibitor, alpha
Rn.12550 -1.52 0.66 1.64 X63594cds_at
Similar to T-cell differentiation antigen (LOC311635), mRNA Rn.25180 -1.51 0.66 2.69 rc_AA799761_at
RT1 class II, locus Bb Rn.20089 -1.49 0.67 4.02 M36151cds_I_at
discs, large homolog 4 (Drosophila) Rn.9765 -1.49 0.67 0.31 M96853_at
Unknown Unknown -1.45 0.69 0.31 X03347cds_g_at
myosin heavy chain 11 Rn.94969 -1.45 0.69 5.03 X16261_i_at
peroxiredoxin 6 Rn.42 -1.45 0.69 2.08 AF014009_at
macrophage galactose N-acetyl-galactosamine specific lectin Rn.779 -1.44 0.69 2.89 J05495_at
protein tyrosine phosphatase, receptor type, N Rn.11097 -1.44 0.70 3.49 D38222_s_at
Transcribed sequences Rn.4292 -1.43 0.70 3.49 rc_AA799347_at
Transcribed sequences Rn.6676 -1.43 0.70 5.03 rc_AA800971_at
Rat mRNA for beta-tubulin T beta15 Rn.37849 -1.42 0.70 1.38 X03369_s_at
Similar to RIKEN cDNA 4930415K17 (LOC291670), mRNA Rn.105695 -1.41 0.71 2.08 rc_H33001_at
Similar to DNA segment, Chr 19, ERATO Doi 386,
expressed (LOC361064), mRNA
Rn.30496 -1.41 0.71 4.54 rc_AA892753_s_at
Transcribed sequences Rn.6620 -1.39 0.72 1.13 rc_AA800693_g_at
hydroxysteroid 11-beta dehydrogenase 1 Rn.888 -1.39 0.72 1.13 rc_AI105448_at
disks large-associated protein 4 Rn.11279 -1.38 0.72 2.89 U67140_g_at
calreticulin Rn.974 -1.38 0.72 2.89 D78308_at
solute carrier family 2,member 1 Rn.3205 -1.38 0.72 1.17 S68135_s_at
calcium/calmodulin-dependent protein kinase II alpha subunit Rn.107499 -1.38 0.72 2.08 J02942_at
Similar to 26S proteasome non-ATPase regulatory subunit 11
(26S proteasome regulatory subunit S9) (26S proteasome
regulatory subunit p44.5) (LOC303353), mRNA
Rn.11861 )1.38 0.72 1.17 rc_AA892831_s_at
Rgc32 protein Rn.3504 -1.38 0.73 2.69 AF036548_at
Jun-B oncogene Rn.15806 -1.38 0.73 2.34 rc_AA891041_at
endothelin converting enzyme-like 1 Rn.45803 -1.37 0.73 1.17 Y16188_at
Transcribed sequences Rn.3130 -1.37 0.73 1.17 rc_AA874803_g_at
c-fos oncogene Rn.103750 -1.37 0.73 1.64 X06769cds_at
Similar to cDNA sequence BC019776 (LOC316842), mRNA Rn.64557 -1.37 0.73 2.10 rc_AI639012_at
Similar to Tubulin alpha-4 chain (Alpha-tubulin 4)
(LOC316531), mRNA
Rn.92961 -1.36 0.73 4.54 rc_AA800948_at
Unknown Unknown -1.36 0.73 1.17 S82649_s_at
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Table 4 Continued
Gene Title UniGene ID Fold Change Deaf / Normal q-value (%) Probe Set ID
Similar to guanylate kinase (LOC303179), mRNA Rn.36522 -1.36 0.73 0.31 rc_AA800291_at
Unknown Unknown -1.36 0.73 0.31 U17837UTR#1_at
farensyl diphosphate synthase Rn.2848 -1.36 0.73 1.38 rc_AI180442_at
nerve growth factor, gamma Rn.11331 -1.36 0.74 5.03 M19647_i_at
Unknown Unknown -1.36 0.74 4.54 AFFX-BioB-5_at
ATP synthase, H+ transporting, mitochondrial
F1 complex, delta subunit
Rn.3879 -1.35 0.74 5.03 U00926_at
ATP synthase, H+ transporting, mitochondrial
F1 complex, epsilon subunit
Rn.3454 -1.35 0.74 1.64 rc_AI171844_g_at
mast cell protease 4 Rn.10698 -1.34 0.74 2.10 U67907_f_at
Similar to R31449_3 (LOC314641), mRNA Rn.2928 -1.34 0.74 1.17 rc_AA799473_at
calcium/calmodulin-dependent protein kinase
(CaM kinase) II gamma
Rn.10961 -1.34 0.75 4.02 U73503_at
Transcribed sequence with weak similarity to protein
ref:NP_075568.1 (H.sapiens) hypothetical
protein FLJ20989 [Homo sapiens]
Rn.2859 -1.34 0.75 2.89 rc_AA891551_at
Similar to cation-transporting atpase (LOC290673), mRNA Rn.3697 -1.33 0.75 1.64 rc_AA893621_at
Similar to 17,000 dalton myosin light chain
(LOC362816), mRNA
Rn.969 -1.33 0.75 3.49 rc_AA875523_i_at
apolipoprotein A-I Rn.10308 -1.33 0.75 4.54 J02597cds_s_at
tumor-associated protein 1 Rn.32261 -1.32 0.76 2.89 AB015432_s_at
Similar to DGCR6 protein (DiGeorge syndrome critical
region 6 homolog) (LOC303794), mRNA
Rn.22467 -1.32 0.76 1.38 rc_AA799732_at
Similar to 2700038E08Rik protein (LOC293725), mRNA Rn.43300 -1.32 0.76 2.10 rc_AA860024_at
ribosomal protein L14 Rn.108039 -1.32 0.76 3.49 X94242_at
Transcribed sequence with strong similarity to protein
ref:NP_062269.1 (M.musculus) cysteine and histidine rich 1;
cysteine and histidine-rich cytoplasmic protein [Mus musculus]
Rn.8316 )1.32 0.76 5.03 rc_AA891802_at
prepronociceptin Rn.87935 -1.32 0.76 0.63 S79730_s_at
Similar to KIAA1064 protein (LOC308385), mRNA Rn.98823 -1.32 0.76 0.31 rc_AA893980_at
methylenetetrahydrofolate reductase Rn.10494 -1.31 0.76 5.03 U57049_at
Rgc32 protein Rn.3504 -1.31 0.76 3.49 AF036548_g_at
Unknown Unknown -1.31 0.76 5.03 L48618_at
CDNA clone MGC:72845 IMAGE:6917939, complete cds Rn.119365 -1.31 0.76 4.54 rc_AI103236_at
Transcribed sequence with strong similarity to protein
ref:NP_037465.1 (H.sapiens) EH domain-binding
mitotic phosphoprotein [Homo sapiens]
Rn.14814 )1.30 0.77 1.17 rc_AA893612_at
von Hippel-Lindau syndrome homolog Rn.11059 -1.30 0.77 0.63 U14746_at
ATP synthase, H+ transporting, mitochondrial
F1 complex, epsilon subunit
Rn.3454 -1.30 0.77 5.03 rc_AI171844_at
solute carrier family 12, member 2 Rn.11523 -1.30 0.77 5.03 AF086758_at
Similar to tumor-rejection antigen SART3 (LOC304582), mRNA Rn.101480 -1.30 0.77 0.31 rc_AI639476_s_at
phosphoglycerate mutase 1 Rn.123549 -1.30 0.77 4.02 rc_AI169417_s_at
Transcribed sequence with moderate similarity to protein
ref:NP_037529.1 (H.sapiens) over-expressed breast
tumor protein [Homo sapiens]
Rn.1327 )1.30 0.77 5.03 rc_AA891796_at
Similar to hypothetical protein MGC6696 (LOC293719), mRNA Rn.2847 -1.29 0.77 0.63 rc_AA800039_s_at
Max Rn.4210 -1.29 0.77 2.10 D14448_s_at
Transcribed sequence Rn.114062 -1.29 0.77 2.34 rc_AA892154_g_at
lactate dehydrogenase A Rn.107896 -1.29 0.77 2.34 M54926_at
ATP synthase, H+ transporting, mitochondrial
F1 complex, delta subunit
Rn.3879 -1.29 0.77 5.03 U00926_g_at
ribosomal protein L18 Rn.484 -1.29 0.78 4.02 M20156_at
phosphodiesterase 4A Rn.91357 -1.29 0.78 2.10 M26715_at
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immunolabeling to be striking for any of the antibodies used,
either in the number of labeled elements and/or the intensity
of labeling. However, for many of these proteins there were
large enough changes in immunolabeling in the 90-day deaf
group compared with labeling in the normal hearing control
group (Figs 2 and 3) to be obviously different in a qualitative
appraisal.
GABA receptor subunit immunolabeling
Numerous neurons were immunolabeled for GABA b3
throughout the three regions of the IC of normal hearing
animals with the labeling having a punctate appearance and
many prominent neurons located throughout the nucleus with
the fewest labeled neurons observed in the central nucleus
(Fig. 2a). In deafened animals the neuropil labelling was
comparable with modestly increased levels of label in 3-day
and 21-day deaf groups, but the 90-day deaf group was
strikingly increased compared with the 3-day and 21-day deaf
groups and controls, with the label for the subunit outlining
many neurons, including several primary dendrites (Fig. 2b).
Neurons immunostained for the c2 subunit of the GABA-A
receptor were also distributed throughout the IC, with a
punctate label filling the somata of the cells. A large number of
these neurons were found in the central nucleus (Fig. 2c). In
animals deafened for 3 days, neither the distribution nor the
number of neurons immunostained for the c2 subunit appeared
to change, nor did the intensity of labeling. However, in the 21-
day and 90-day deafened groups the number of labeled cells
increased, particularly in the central nucleus of the IC (Fig. 2d)
with more primary dendrites being labeled.
Glutamate receptor subunit immunolabeling
An antibody that immunolabels glutamate receptors contain-
ing both the 2 and 3 subunits (GluR 2/3) was used. GluR 2/3
immunolabel filled cell bodies and the labeling was found
primarily in small to medium-sized cells (£ 20 lm) scattered
throughout the central nucleus of the IC. No obvious
differences in labeling were found in the 3- and 21-day deaf
groups compared with that of the control group, with a
modest increase in the 90-day deaf group in the number of
labeled cells. Immunolabeled neurons formed clusters or
patches within the central nucleus of the IC (Fig. 2e) that
become more prominent in the 90-day deaf group (Fig. 2f).
Neuropeptide immunolabeling
In normal animals there were very few PENK labeled cell
bodies observed in the IC. However, there were labeled fibers
and puncta throughout the nucleus, with a higher concentra-
tion of label in the dorsal cortex (Fig. 3a). While there was
no apparent diminution of label in the 3- and 21-day deaf
groups when compared with the control group, in the 90-day
deaf group there was a general decrease in labeling of fibers
and puncta in deafened animals (Fig. 3b) with fairly intense
labeling maintained in the dorsal cortex.
Table 4 Continued
Gene Title UniGene ID Fold Change Deaf / Normal q-value (%) Probe Set ID
solute carrier family 2,member 1 Rn.3205 -1.28 0.78 1.64 M13979_at
Transcribed sequences Rn.98517 -1.28 0.78 2.34 rc_AA800719_at
ATPase, vacuolar, 14 kD Rn.6167 -1.28 0.78 4.54 U43175_at
potassium voltage-gated channel, KQT-like subfamily,
member 1
Rn.9779 -1.28 0.78 1.46 U92655_at
Similar to eukaryotic translation initiation factor 3 subunit 7;
eukaryotic translation initiation factor 3, subunit
7 (zeta, 66/67kD); translation initiation factor eIF3 p66
subunit (LOC362952), mRNA
Rn.3463 )1.28 0.78 2.89 rc_AA891553_at
myosin heavy chain, polypeptide 7 Rn.48663 -1.27 0.78 2.10 X15939_f_at
insulin 1 Rn.962 -1.27 0.79 2.34 E00001cds_f_at
major intrinsic protein of eye lens fiber Rn.23532 -1.27 0.79 4.54 X53052cds_g_at
peroxiredoxin 6 Rn.42 -1.27 0.79 5.03 rc_AA892041_at
nucleoside diphosphate kinase Rn.927 -1.27 0.79 5.03 M91597_s_at
Transcribed sequences Rn.13477 -1.27 0.79 2.69 rc_AA893124_at
c-fos oncogene Rn.103750 -1.27 0.79 2.89 X06769cds_g_at
laminin receptor 1 (67kD, ribosomal protein SA) Rn.999 -1.26 0.79 1.64 D25224_at
proline-rich protein 15 Unknown -1.26 0.79 2.34 M83567_s_at
isovaleryl coenzyme A dehydrogenase Rn.147 -1.26 0.79 2.69 rc_AI102838_s_at
Tonin Rn.9882 -1.26 0.79 4.02 M26534_i_at
Similar to non-receptor protein tyrosine kinase Ack
(LOC303882), mRNA
Rn.98335 -1.26 0.79 2.69 rc_H31144_g_at
methyl CpG binding protein 2 Rn.9680 -1.26 0.79 2.69 M94064_at
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Tyrosine hydroxylase immunolabeled neurons were found
throughout the IC of normal animals. However, there were so
many intensely immunolabeled fibers and puncta observed
throughout the IC, immunolabeling of cells was obscured.
Specifically, bundles of immunolabeled fibers were found
coursing through the dorsal cortex (Fig. 3c). While there was
only a slight decrease in labeling in the 3-day deaf group,
there were dramatic reductions in labeled cells and fibers in
the 21-day and 90-day deaf groups throughout the IC when
comparing deafened (Fig. 3d) and normal hearing animals
(Fig. 3c).
Discussion
GeneChip analysis using SAM identified large numbers of
genes as showing significant differential expression across
groups in the rat IC 3 and 21 days following bilateral
cochlear ablation. The level of expression and the magnitude
of change are also often considered when assigning
functional relevance to an identified change in expression.
We have chosen not to add these constraints to our
assessment as, even small changes, when they appear
consistently (as shown by a test of significance), can have
functional implications. Information on magnitude of chan-
ges in gene expression, however, is reported in Table 5.
Activity-dependent changes in the expression of several
genes shown to be differentially expressed, including,
tyrosine kinase, JUN, EGR1, calbindin, MAP and protein
kinase C (PKC), have previously been demonstrated in the
auditory brainstem (Garcia et al. 2000; Illing 2001; Kotak
and Sanes 2002; Michler and Illing 2003; Zhang et al.
2004). Increased neuronal activity is known to activate
immediate early genes C-FOS, JUN and EGR1 (Akins
et al. 1996), which are often used as markers of neuronal
Table 5 Comparison of gene expression 3 and 21 days after deafening: GeneChip vs qRT-PCR data
Gene Name unigene id
3 day vs. control 21 day vs. control 90 day vs. controlc
GeneChipa qRT-PCRb GeneChipa qRT-PCRb qRT-PCRb
GLUTAMATE RELATED GENES
glutamate receptor, ionotropic, 2 d Rn.91361 1.70 2.67 1.61 2.87 1.70
glutamate receptor, ionotropic, 2 d Rn.91361 1.53 2.67 1.23 2.87 1.70
glutamate receptor, ionotropic, 3 Rn.74049 1.25 3.34 1.07 2.95 2.73
glutamate receptor, ionotropic, kainate 2 Rn.87696 1.32 2.47 1.23 2.61 1.67
glutaminase (gls) Rn.5762 1.52 3.50 1.44 3.13 2.62
glutamine synthetase 1 (glns) Rn.2204 no change — -1.14 — -1.32
GABA RELATED GENES
GABA A receptor b 2 Rn.48880 1.61 4.42 no change 4.26 3.35
GABA A receptor b 3 Rn.53967 1.48 3.07 no change 2.81 2.62
GABA A receptor g 1 Rn.10366 1.33 — 1.41 1.48 —
GABA A receptor g 3 Rn.103894 1.88 2.15 2.05 2.37 1.70
glutamate decarboxylase 2 (GAD 65) Rn.29951 1.41 1.28 1.52 1.51 1.33
GLYCINE RELATED GENES
glycine a 1 Rn.10109 no change — no change 1.30 1.39
glycine a 2 Rn.10379 1.56 — 1.57 2.86 —
glycine a 3 Rn.10038 no change 2.37 no change 3.54 2.50
OTHER GENES
5-hydroxytryptamine (serotonin) receptor 5B Rn.10572 no change -1.22 -1.17 -1.19 —
5-hydroxytryptamine (serotonin) receptor 2C d Rn.9935 1.39 2.19 1.65 2.18 2.30
5-hydroxytryptamine (serotonin) receptor 2C d Rn.9935 no change 2.19 1.86 2.18 2.30
preproenkephalin, related sequence Rn.10015 -1.82 — -1.82 -1.22 -1.25
prepronociceptin (neuropeptide nociceptin) (N23K) Rn.87935 no change -1.69 -1.32 -2.27 -1.40
activity and neurotransmitter-induced early
gene protein 4 (ania-4)
Rn.80575 1.28 1.18 1.33 -7.14 -7.89
tyrosine hydroxylase Rn.11082 no change -2.33 -1.18 -2.04 -2.28
a. Change in intensity, expressed as fold change
b. Expressed as fold change (2|DDCt| ), with the decreased expression indicated by a minus sign.
Note: The exponent in the fold change calculation is expressed as an absolute value.
c. No GeneChips run for this group
d. Same gene but different probe set on GeneChip
— Less that 15% change
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activity. As expected, JUN and EGR1 showed large
decreases in expression following deafening. The present
study also demonstrated changes in the levels of mRNA for
various neurotransmission-related genes that have been
studied previously. Our results are consistent with and
extend previous analyses.
Glutamate receptor modulation
There are several receptor subtypes responsible for the
binding of excitatory neurotransmitter. In our study, the
level of expression for two AMPA receptor subunits
(GlurR 2 and GluR 3) and one kainate receptor subunit
(GluR K2) were significantly higher at all times following
deafening. The GluR 2–GluR 3 receptor combination is
believed to be continuously delivered to the synapse in a
non-activity-dependent manner, while the GluR1–GluR2
receptor combination, as well as those containing GluR 4,
are delivered to the synapse in an activity-dependent
manner (Malinow et al. 2000; Passafaro et al. 2001; Shi
et al. 2001).
Genes for ras, CamK2, mitogen-activated protein kinase,
and protein kinase A, each implicated in the insertion of
AMPA receptors into the synapse, showed increased expres-
sion. Gene expression for PKC and rap, implicated in the
removal of AMPA receptors from the synapse, also
increased. This may indicate a high rate of turn-over/delivery
of the constitutive receptor (GluR2–GluR3) and an increase
in the insertion of the more plastic receptor combination
containing the GluR 1 and GluR 2 receptor subunits. We
also found decreased expression of glutamine synthetase, a
key enzyme in the recycling of glutamate and increased
expression of glutaminase, an enzyme that catalyzes the
reaction of glutamine to glutamate.
GABA-related genes
The current study demonstrated sustained increases in the
expression in three GABA-A receptor subunit types, with
high levels of expression for b2, b3 and c2 even at 90 days
following bilateral cochlear ablation. This suggests compen-
satory postsynaptic mechanisms that increase expression of
these inhibitory receptors at the synapse when presynaptic
transmitter function decreases.
The GABA-A c2 receptor subunit plays a role in transport
and placement of the receptor complexes (Kittler and Moss
2003; Schweizer et al. 2003). We found increased expres-
sion of the GABA-A c2 subunit along with differential
expression of other genes associated with placement of
functional receptors into the synapse, such as clathrin (Lee
et al. 2002; Blanpied et al. 2003), dynamin (Okamoto et al.
2001; Bobanovic et al. 2002; Carvelli et al. 2002), and
adaptor protein-2 (Kittler et al. 2002). There was also
increased expression of cAMP-dependent protein kinase,
PKC, and tyrosine kinase which modulate GABA receptors
through phosphorylation of b and c subunits. Interestingly,
we found increased expression of b3 subunits where
phosphorylation leads to increased activity of the receptor,
perhaps leading to more ‘sensitive’ GABA-A receptors
following deafness.
Glycine receptor modulation
Studies (Kungel et al. 1997; Piechotta et al. 2001) have
found low levels of expression of the ‘immature’ glycine
receptor a2 subunit in post-natal animals. We found
increased expression of the inhibitory receptor’s a2 subunit
following deafness. The a2 subunit may confer such
functional properties as a mean increase in channel open
time (Takahashi et al. 1992; Mangin et al. 2002), an increase
of the desensitization constant, and an increase in the
duration of the postsynaptic current. The function of glycine
receptors has been shown to be enhanced by phosphorylation
of a subunits by cAMP-dependent protein kinase, calcium-
dependent calmodulin kinase II (CamK), PKC (Legendre
2001) and the glycine b subunit by tyrosine kinase (Carais-
cos et al. 2002), all of which increased in expression in the
current study with the exception of CamK2a and CamK2g
which decreased in expression.
Other neurotransmission-related genes
There was decreased TH in the IC following deafness, which
correlates well with recent findings by Niu et al. (2004) that
acoustic trauma decreases TH in the lateral olivocochlear
system. Nociceptin and enkephalin also showed decreased
(a) (b)
(c) (d)
Fig. 1 Neurotransmitter-related genes are differentially expressed
following deafferentation. Bar graphs of qRT–PCR showing differential
gene expression of glutamate-related (a), GABA-related (b), glycine-
related (c) and neuropeptide-related (d) genes following bilateral
cochlear ablation. Data are expressed as a ratio, gene expression
from deafened animals divided by gene expression from normal ani-
mals. Grey bars represent gene expression from 3-day deaf animals,
black bars represent expression levels of 21-day deaf groups and
white bars represent expression from 3-month deaf animals. Only two
of the 19 genes tested (GlyR a2 and 5-HT 5B) had returned to normal
levels of expression by 90 days.
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expression in the current study. Nociceptin receptor knockout
mice have a longer recovery period when compared with
wild-type mice following noise exposure (Nishi et al. 1997),
suggesting a protective role for nociceptin. Serotonin recep-
tors are present in the IC (Li et al. 2004), and have a
purported role in synaptogenesis (Niitsu et al. 1995) and
neuronal plasticity (Julius 1991; Kojic et al. 2000). Many of
the differentially expressed neuropeptide-related genes have
been implicated in the modulation of GABA, glycine, and/or
glutamate receptor function. For example, serotonin recep-
tors (Cai et al. 2002) regulate GABA-A receptor activity.
Dopamine can enhance kainate receptor-mediated activity
(Knapp and Dowling 1987). In addition, opiates can exert an
inhibitory affect on AMPA and kainate receptors (Kolaj and
Randic 1996).
Other functionally related groups
Previous studies of auditory brainstem plasticity found
that deafness affects ion channels (Li et al. 2001;
Sivaramakrishnan and Oliver 2001; Tzounopoulos and
Stackman 2003; von Hehn et al. 2004). We found potas-
sium inwardly rectifying channel, subfamily J, members 4
and 11 decreased at both 3 and 21 days, while the
potassium voltage-gated channels, Shal-related family,
members 2 and 3 increased at 21 days and the potassium
voltage-gated channel, KQT-like subfamily, member 1
decreased in expression at 21 days.
Changes in expression of genes associated with deafness-
related changes in cell size, dendrites, dendritic spines and
synaptic characteristics might be expected. We found the
cytoskeleton-related genes Map 2, laminin c1, protein kinase
Fig. 2 Changes in immunoreactivity for
GABA (a–d) and glutamate (e, f) receptor
subunits in the central nucleus of the inferior
colliculus. Photomicrographs of subunits for
GABA-A b3 (a, b) GABA-A c2 (c, d) and
GluR 2/3 (e, f) receptor immunoreactive
cells and/or fibers. Immunoreactivity from
animals deafened for 90 days (b, d, f) is
more robust when compared with labeling
from normal animals (a, c, d). Following
deafness, the labeling for GABA-A b3 and
GABA-A c2 is found in more primary
dendrites (arrows in b and d) when com-
pared with labeling in the normal hearing
group (a, c). Labeling for GluR 2/3 is pri-
marily concentrated in the soma of the
neuron in the normal hearing group (arrow
in e), however, following deafness the
neuropil shows more label (f). Calibration
bar ¼ 100 lm.
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2 and 6, and ankyrin all increased in expression, while Map
Tau and ARC decreased. Genes involved in vesicular
trafficking such as SNAP 25, Munc 13–3, and synaptic
vesicle glycoprotein 2b increased, while synaptic vesicle
glycoprotein 2a decreased in expression.
Several stress-related genes increased in expression and
remained increased at 21 days following deafening. These
included heat shock proteins 40, 60 and 86, as well as
caspase 2, nucleostemin, super oxide dismutase 2, and cyclin
(L and G1).
Second messenger-related genes can have direct effects on
gene expression and protein production. In this study, the
G-protein receptor-related genes endothelin receptor type B,
neuropeptide Y receptor Y1, neuropeptide Y receptor Y5,
and the cannabinoid receptor 1 gene increased at 21 days,
and prostaglandin E receptor 4 (subtype EP4), adrener-
gic receptor, alpha 2c, galanin receptor 1, gonadotropin-
releasing hormone receptor, cholecystokinin B receptor,
neurotensin receptor 2, and angiotensin II receptor, type 1
(AT1A) decreased.
Given the many genes differentially expressed, there
should also be changes in genes involved in regulation of
transcription. We found decreased expression of methyl CpG
binding protein 2 (MeCP2), which normally acts to repress
gene transcription. This decreased expression could be
coupled to increased transcription of some of its target genes
although, in this study, one such target, brain derived
neurotrophic factor (BDNF), showed decreased expression.
Decreased expression of both BNDF and PENK in the
current study is interesting in the context of recent studies
which showed that application of an enkephalin agonist
increases BDNF expression in frontal cortex and hippocam-
pus (Torregrossa et al. 2004). Bone morphogenetic protein
(BMP), an important signaling molecule, is modulated by a
group of BMP antagonists. We found increased expression of
BMP-4B, along with decreased expression of noggin, one of
the major BMP antogonists. Up-regulation of BMP-4B
expression and down-regulation of the BMP-antagonist
noggin would lead to increased BMP4 signaling through
associated SMADs. Other genes in the GO transcriptional
regulation classification that increased in expression included
cadherin 2, myosin Ib, myelin-associated oligodendrocytic
basic protein, and vascular endothelial growth factor recep-
tor. While Delta-like 1 (Drosophila) had decreased expres-
sion.
Technical considerations
We found excellent correspondence in the direction and
amount of change with GeneChip analysis and qRT-PCR for
most genes at most times following deafness. However, in
the 3-day deaf group GABA c1 and glycine a2 receptor
subunits showed 33 and 56% increases, respectively, in the
GeneChip analysis, while there was no significant change in
either by qRT–PCR. qRT–PCR did show increases in both
GABA c1 and glycine a2 receptor subunits at 21 days. In
the 21-day deaf group, neurotransmitter-induced early gene
protein had only minor expression changes in GeneChip
analysis and a 64% increase and 86% decrease, respectively,
by qRT–PCR. Glycine receptor a1 and a3 subunits did not
show significant changes in the GeneChip analysis but
showed increases by qRT–PCR, at 21 and 90 days, a modest
increase for a1 and large increases for a3. Neurotransmis-
sion-related genes often have low levels of constitutive
expression and may therefore prove more challenging when
trying to detect changes in such genes by GeneChip analysis
when compared with qRT–PCR, perhaps a more sensitive
measure. We performed qRT–PCR analysis on eight genes
with low FDRs, but small changes in expression (ratio less
than 1.5) at 3 days following deafness. Six of eight showed
greater changes in expression levels by qRT–PCR.
The low constitutive expression of neurotransmission-
related genes may contribute to the greater variability in
intensity levels, as measured by GeneChip analysis. The
present study addresses the issue of variability by using an
Fig. 3 Changes in immunoreactivity for enkephalin (a, b) and tyrosine
hydroxylase (c, d) in the central nucleus of the inferior colliculus.
Immunoreactivity is decreased in 90-day deaf animals (b, d) when
compared with immunoreactivity from normal animals (a, c). Calibra-
tion bar ¼ 100 lm.
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increased sample size, using RMA for normalization that
more accurately reflects the expression level of genes, as well
as using a statistical method sufficiently stringent in assign-
ing significance. We used SAM to compare gene expression
of deafened and normal animals, and to calculate the FDR. A
surprisingly large number of genes showed FDRs of 5% or
less, suggesting that increased numbers of replicates and
RMA can enhance the sensitivity of microarray analysis.
Decreasing variability allowed identification of numerous
and diverse activity-dependent genes within the inferior
colliculus.
We then followed these experiments and analyses with
qRT–PCR and immunocytochemical studies for a represen-
tative population of our data that we hypothesized would be
responsive to decreased activity. Although the specific cell
types that undergo modulation as a result of deafness were
not differentiated in this examination, we were able to detect
changes in both the quantity and intensity of immunolabeling
within the central nucleus of the inferior colliculus. The
genes that were confirmed with these methods may play an
important role in deafness-related plasticity and merit further
study in other nuclei within this system. Additionally, many
of the other genes identified as differentially expressed in
Tables 1–5 and Tables S2 and S3, but not further examined
in our study, may also be important and warrant further study.
The present study provides evidence that gene microarrays
can provide a useful method for studying deafness-induced
plasticity in the central auditory system. By surveying a large
pool of neurotransmitter-related genes, we have been able to
identify important patterns of expression among these genes.
In response to 3 and 21 days of deafness, within the IC, the
system seems to compensate for decreased inhibitory input
by increasing the expression of highly efficacious inhibitory
receptors as well as the molecular machinery necessary for
more efficient delivery of these receptors to the synapse.
Future studies will include examining different times after
deafness as well as studies in additional auditory brainstem
regions.
Our results lay the groundwork for future studies that can
focus on specific genes, identified in the present study, in
greater detail. Certainly, the genes that have not returned to
normal levels of expression by the latest time assessed in this
study will be of particular interest when considering return of
hearing with cochlear prostheses, at different times following
deafness. Indeed, there is a correlation between how well a
post-lingually deafened patient responds to the cochlear
prosthesis and the duration of deafness, with those implanted
at earlier times following deafness having the best outcomes
(Kileny et al. 1991; Blamey et al. 1992; Gantz et al. 1993).
Results of the current study will also provide a normative
database and metric to examine reversal at different times
following deafness, relationships that have not previously
been studied in much detail.
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